NxCare and ERSP
This article was originally published in The Tan Sheet
NxCare is asked by the Electronic Retailing Self-Regulatory Program to discontinue product superiority claims and modify weight-loss related performance claims for its Methyl Ripped fat burner product in a decision announced Dec. 8. Claims reviewed by ERSP include: "Bodybuilding's strongest fat burner" and "Methyl Ripped's formula goes to work quickly obliterating fat." The watchdog program determined NxCare's submitted testing results did not adequately support "all reasonable interpretations" communicated by the claims and recommended modifying or discontinuing them. ERSP also recommends NxCare increase the text size of disclosure language accompanying consumer testimonials to be made "more clear and conspicuous"...
You may also be interested in...
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.